PMID-38095657 – Survodutide Phase 2 Type 2 Diabetes
Blundell J, Finlayson G, Axelsen M, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470-482.
Quick Reference
| Property | Value |
|---|---|
| PMID | 38095657 |
| DOI | 10.1007/s00125-023-06053-9 |
| Year | 2024 |
| Journal | Diabetologia |
| Study Type | RCT (Phase 2) |
| Evidence Level | II |
| Sample | n=414 adults with type 2 diabetes |
| Peptide(s) Studied | Survodutide |
Key Findings
- HbA1c reductions were dose-dependent: up to -1.71% with survodutide vs. -0.38% with placebo
- Body weight decreased dose-dependently up to -8.7% with survodutide
- Survodutide doses >=1.8 mg produced greater bodyweight reductions than open-label semaglutide 1.0 mg
- The dual GLP-1/glucagon mechanism showed additive metabolic benefits
- Fasting glucose improvements were dose-dependent
- GI adverse events were the most common treatment-emergent events
- Heart rate increases were observed (consistent with GLP-1 RA class effects)
- Improvements in lipid profiles observed across dose groups
Study Design
Phase 2, randomised, double-blind, placebo-controlled trial with an open-label semaglutide 1.0 mg comparator arm. Adults with T2D (HbA1c 7.0-10.5%) were randomized to survodutide at escalating doses (0.3 to 4.8 mg), placebo, or open-label semaglutide 1.0 mg once weekly for 16 weeks. Primary endpoint was HbA1c change from baseline.
Limitations
- Short treatment duration (16 weeks)
- Open-label semaglutide arm introduces potential bias
- Semaglutide comparator was 1.0 mg (not 2.4 mg obesity dose)
- Phase 2 design with dose-exploration focus
- Limited sample size per dose group
Clinical Relevance
This trial demonstrated that survodutide's dual GLP-1/glucagon agonism translates into superior weight loss vs. semaglutide at equivalent treatment durations, while providing robust glycemic control. The glucagon component's contribution to energy expenditure and hepatic glucose regulation adds mechanistic value beyond pure GLP-1 RA therapy. For practitioners, this positions survodutide as a potential advancement over single-pathway GLP-1 RAs, particularly for T2D patients with concurrent obesity and NAFLD/MASH.
Related
#research #RCT #evidence-level-II #metabolic #survodutide #investigational